We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.
Chimenti, S., Carrozzo, A.m., Citarella, L., De Felice, C., Peris, K. (2004). Treatment of lentigo maligna with tazarotene 0.1% gel. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 50(1), 101-103 [10.1016/j.jaad.2003.07.005].
Treatment of lentigo maligna with tazarotene 0.1% gel
CHIMENTI, SERGIO;CARROZZO, ANNA MARIA;
2004-01-01
Abstract
We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Treatment of lentigo maligna with tazarotene 0.1% gel.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
169.63 kB
Formato
Adobe PDF
|
169.63 kB | Adobe PDF | Visualizza/Apri |
Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
